Hepion Pharmaceuticals Statistics
Share Statistics
Hepion Pharmaceuticals has 10.93M
shares outstanding. The number of shares has increased by -89.82%
in one year.
| Shares Outstanding | 10.93M |
| Shares Change (YoY) | -89.82% |
| Shares Change (QoQ) | -89.99% |
| Owned by Institutions (%) | 9.38% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 448.18K, so 4.08% of the outstanding
shares have been sold short.
| Short Interest | 448.18K |
| Short % of Shares Out | 4.08% |
| Short % of Float | 4.08% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.22 and the forward
PE ratio is null.
Hepion Pharmaceuticals's PEG ratio is
0.
| PE Ratio | -0.22 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | -1.55 |
| P/FCF Ratio | -0.16 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Hepion Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.51,
with a Debt / Equity ratio of -1.56.
| Current Ratio | 0.51 |
| Quick Ratio | 0.51 |
| Debt / Equity | -1.56 |
| Debt / EBITDA | -0.15 |
| Debt / FCF | -0.16 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-599,655.45 |
| Employee Count | 22 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -2.97M |
| Effective Tax Rate | 18.37% |
Stock Price Statistics
The stock price has increased by null% in the
last 52 weeks. The beta is 1.9, so Hepion Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 1.9 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 1.11 |
| 200-Day Moving Average | 21.39 |
| Relative Strength Index (RSI) | 26.97 |
| Average Volume (20 Days) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -19.35M |
| Net Income | -13.19M |
| EBITDA | -19.35M |
| EBIT | -17.41M |
| Earnings Per Share (EPS) | -107.35 |
Full Income StatementBalance Sheet
The company has 406.41K in cash and 2.9M in
debt, giving a net cash position of -2.49M.
| Cash & Cash Equivalents | 406.41K |
| Total Debt | 2.9M |
| Net Cash | -2.49M |
| Retained Earnings | -237.82M |
| Total Assets | 1.61M |
| Working Capital | -1.53M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -18.22M
and capital expenditures 0, giving a free cash flow of -18.22M.
| Operating Cash Flow | -18.22M |
| Capital Expenditures | n/a |
| Free Cash Flow | -18.22M |
| FCF Per Share | -148.23 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
